Inventor · disambiguated record
Li Zhou
Also filed as: ZHOU LI · Zhou li-juan
13 granted patents·25 pending applications·107 citations·filing 2005–2025
90Inventor score
Files withNOVARTIS AG11SHANDONG BOAN BIOTECHNOLOGY CO LTD7AMPSOURCE BIOPHARMA SHANGHAI INC2MONSANTO TECHNOLOGY LLC2UNIV BRITISH COLUMBIA2
Top patents by PatentIndex Score
38 records- 0196US10253086B2CD20 therapies, CD22 therapies, and combination therapies with a CD19 chimeric antigen receptor (CAR)-expressing cellNOVARTIS AG·Filed 2016·Granted Apr 9, 2019·37 cites·35 claims
- 0294US11149076B2CD20 therapies, CD22 therapies, and combination therapies with a CD19 chimeric antigen receptor (CAR)-expressing cellNOVARTIS AG·Filed 2019·Granted Oct 19, 2021·9 cites·32 claims
- 0394US10287354B2Regulatable chimeric antigen receptorNOVARTIS AG·Filed 2014·Granted May 14, 2019·29 cites·63 claims
- 0489US12344657B2CD20 therapies, CD22 therapies, and combination therapies with a CD19 chimeric antigen receptor (CAR)-expressing cellNOVARTIS AG·Filed 2021·Granted Jul 1, 2025·1 cites·27 claims
- 0588US9290573B2Therapeutic low density lipoprotein-related protein 6 (LRP6) multivalent antibodiesCONG FENG·Filed 2011·Granted Mar 22, 2016·16 cites·9 claims
- 0687US8883735B2Low density lipoprotein-related protein 6 (LRP6)-half life extender constructsNOVARTIS AG·Filed 2012·Granted Nov 11, 2014·8 cites·34 claims
- 0783US11578130B2Regulatable chimeric antigen receptorNOVARTIS AG·Filed 2018·Granted Feb 14, 2023·1 cites·30 claims
- 0882US11175289B2Application of TRPM8 protein, related peptide fragment and their antibodiesHAN LEI·Filed 2016·Granted Nov 16, 2021·3 cites·5 claims
- 0980US2023374105A1Cd20 therapies, cd22 therapies, and combination therapies with a cd19 chimeric antigen receptor (car)-expressing cellNOVARTIS AG·Filed 2023·Application pending·0 cites
- 1077US9173960B2Methods of treating cancer with low density lipoprotein-related protein 6 (LRP6)—half life extender constructsNOVARTIS AG·Filed 2014·Granted Nov 3, 2015·2 cites·30 claims
- 1174US12492252B2Anti-GPC3 antibody, anti-GPC3 chimeric antigen receptor and GPC3/CD3 bispecific antibodySHANDONG BOAN BIOTECHNOLOGY CO LTD·Filed 2021·Granted Dec 9, 2025·1 cites·20 claims
- 1272US2023026049A1Regulatable chimeric antigen receptorNOVARTIS AG·Filed 2022·Application pending·0 cites
- 1367US2024368219A1Activation of e6ap/ube3a-mediated protein ubiquitination and degradation pathways by a cyclic gamma-aa peptideUNIV SOUTH FLORIDA·Filed 2024·Application pending·0 cites
- 1465US2024067732A1Anti-hla-a2 antibodies and uses thereofUNIV BRITISH COLUMBIA·Filed 2023·Application pending·0 cites
- 1564US2009100536A1Transgenic plants with enhanced agronomic traitsMONSANTO CO·Filed 2007·Application pending·0 cites
- 1663US2025368752A1Monoclonal antibody against tfpi and use thereofAMPSOURCE BIOPHARMA SHANGHAI INC·Filed 2023·Application pending·0 cites
- 1760US11814432B2Anti-HLA-A2 antibodies, related chimeric antigen receptors, and uses thereofUNIV BRITISH COLUMBIA·Filed 2018·Granted Nov 14, 2023·0 cites·14 claims
- 1860US2021087279A1Regulatable chimeric antigen receptorNOVARTIS AG·Filed 2020·Application pending·0 cites
- 1960US2025333523A1Anti-IL18 Binding Protein Antibodies and Methods of Use ThereofALECTOR LLC·Filed 2025·Application pending·0 cites
- 2060US2013074202A1Gene sequences and uses thereof in plantsADAMS THOMAS·Filed 2012·Application pending·0 cites
- 2158USRE47860EMethods of treating cancer with low density lipoprotein-related protein 6 (LRP6)—half life extender constructsNOVARTIS AG·Filed 2017·Granted Feb 18, 2020·0 cites·52 claims
- 2258US2011258734A1Gene sequences and uses thereof in plantsMONSANTO TECHNOLOGY LLC·Filed 2011·Application pending·0 cites
- 2358US2025387483A1Bispecific chimeric antigen receptor targeting bcma-cd19 and application thereofJUVENTAS UNICARE PHARMACEUTICAL BEIJING CO LTD·Filed 2023·Application pending·0 cites
- 2457US2024336903A1Fusion Proteins for Dephosphorylating Proteins that Regulate T Cell Activation through the TCR Signaling PathwaySHANDONG BOAN BIOTECHNOLOGY CO LTD·Filed 2022·Application pending·0 cites
- 2556US2024317857A1Anti-cd3 antibody and use thereofAMPSOURCE BIOPHARMA SHANGHAI INC·Filed 2022·Application pending·0 cites
- 2656US2023355764A1Downregulation of membrane-bound proteins by receptor tac technologySHANDONG BOAN BIOTECHNOLOGY CO LTD·Filed 2021·Application pending·0 cites
- 2756US2023272040A1Stealth chimeric antigen receptor and use thereof in reducing cytotoxicity towards normal cellsSHANDONG BOAN BIOTECHNOLOGY CO LTD·Filed 2021·Application pending·0 cites
- 2851US2014325710A1Genes and uses for plant improvementMONSANTO TECHNOLOGY LLC·Filed 2014·Application pending·0 cites
- 2951US2024352016A1A cyclin-dependent kinase inhibitorTAIZHOU EOC PHARMA CO LTD·Filed 2022·Application pending·0 cites
- 3050US2024342283A1ROR1 CAR or ROR1 / CD19 Dual CAR T Cells for the Treatment of TumorsSHANDONG BOAN BIOTECHNOLOGY CO LTD·Filed 2022·Application pending·0 cites
- 3146US2024117035A1Cldn18.2/cd3 bispecific antibodies for the therapy of cldn18.2-expressing solid tumorsSHANDONG BOAN BIOTECHNOLOGY CO LTD·Filed 2022·Application pending·0 cites
- 3246US2017081411A1Regulatable chimeric antigen receptorENGELS BORIS·Filed 2015·Application pending·0 cites
- 3344US2019359653A1Selective peptide inhibitors of frizzledGENENTECH INC·Filed 2019·Application pending·0 cites
- 3443US12312402B2Antibody or chimeric antigen receptor which targets Claudin 18.2SHANDONG BOAN BIOTECHNOLOGY CO LTD·Filed 2020·Granted May 27, 2025·0 cites·20 claims
- 3543US2006041961A1Genes and uses for pant improvementABAD MARK S·Filed 2005·Application pending·0 cites
- 3641US2018127478A1SINGLE CHAIN Fc-DIMER-HUMAN GROWTH HORMONE FUSION PROTEIN FOR IMPROVED DRUG DELIVERYSHEN WEI CHIANG·Filed 2017·Application pending·0 cites
- 3741US2013245233A1Multispecific MoleculesLEI MING·Filed 2011·Application pending·0 cites
- 3835US2008092255A1Methods of producing and using cold temperature tolerant plants, seeds, and cropsEDGERTON MICHAEL D·Filed 2007·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Li Zhou files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →